FOR IMMEDIATE RELEASE: November 11, 2023 In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical …
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
Today, the White House released a statement that President Joe Biden “will grant a pardon to all people convicted of simple marijuana possession under federal law” and “urged governors to take similar …
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
Fifty years after the War on Drugs was officially declared and psychedelic substance prohibition began in contravention of evidence supporting therapeutic use, the California State Senate has taken the …
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
On the heels of United Nations’ Commission on Narcotic Drugs removal of medical marijuana from the list of most dangerous drugs, lawsuit demands processing and approval of licenses to support research …
On February 24, 2017, investigators gathered for the formal closeout of our Phase 2 study of MDMA-assisted psychotherapy in 23 subjects with chronic PTSD in Boulder, Colorado, led by Principal Investigator …
On February 2 and February 7, 2017, the eighth and ninth of 10 participants completed their 12-month follow-up interviews in our Israeli Phase 2 study of MDMA-assisted psychotherapy for PTSD. The seventh …
